News Conference News ESC 2024 Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER Todd Neale August 31, 2024
News Daily News AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients Michael O'Riordan August 26, 2024
News Daily News ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI Michael O'Riordan July 01, 2024
News Conference News EuroPCR 2024 FFR-Derived Metric Can Identify Focal CAD Best Suited to PCI Caitlin E. Cox May 20, 2024
News Daily News AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care L.A. McKeown May 17, 2024
News Conference News EuroPCR 2024 Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS Yael L. Maxwell May 15, 2024
News Daily News TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction Michael O'Riordan May 06, 2024
News Daily News Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift Yael L. Maxwell May 03, 2024
News Conference News ACC 2024 Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC Michael O'Riordan April 08, 2024
Presentation ACC 2024 Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC) Presenter: Rasha K. Al-Lamee April 08, 2024
News Conference News ACC 2024 Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI Shelley Wood April 06, 2024
News Conference News ACC 2024 Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF Michael O'Riordan April 06, 2024
News Opinion Off Script Evoque and Patisiran: A Tale of Two Regulatory Journeys Sanjay Kaul, MD March 29, 2024
News Daily News Biologic Winrevair Wins FDA Approval for Treatment of PAH L.A. McKeown March 27, 2024
News Daily News Risk Factor Control Worse in Women Than Men in ISCHEMIA Trial Todd Neale March 04, 2024
News Daily News DISCHARGE Data Reassure on Use of CCTA in Older Chest-Pain Patients Michael O'Riordan March 04, 2024
News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024